Blue Trust Inc’s Axsome Therapeutics AXSM Stock Holding History

Blue Trust Inc’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$676	Hold	4	–	–	﹤0.01%	2309
2025 Q4	$731	Buy	+4	New	+$558	﹤0.01%	2338
2025 Q2	–	Sell	-113	Closed	-$13.2K	–	2459
2025 Q1	$13.2K	Hold	113	–	–	﹤0.01%	1789
2024 Q4	$9.56K	Buy	113 +38	+51%	+$3.49K	﹤0.01%	1945
2024 Q3	$6.04K	Buy	75 +27	+56%	+$2.36K	﹤0.01%	2348
2024 Q2	$3.83K	Buy	+48	New	+$3.55K	﹤0.01%	2277
2024 Q1	–	Sell	-38	Closed	-$3K	–	2199
2023 Q4	$3K	Buy	+38	New	+$2.54K	﹤0.01%	1982

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blue Trust Inc's AXSM Position: Q1 2026 in Review

Blue Trust Inc held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 4 shares worth $676. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

Blue Trust Inc first reported a position in AXSM in Q4 2023 and has held it in 7 quarters since. The position peaked at $13.2K in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Blue Trust Inc held 4 shares of Axsome Therapeutics worth $676 as of Q1 2026.
Blue Trust Inc left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q1 2026, its #2309 holding.
Blue Trust Inc first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 7 quarters since.
Blue Trust Inc's Axsome Therapeutics position peaked at $13.2K in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Blue Trust Inc's 13F filing for Q1 2026, filed 20 Apr 2026.